Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting a clinical study titled ‘An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease.’ The study aims to assess the long-term safety of inclacumab in individuals with sickle cell disease (SCD) who have previously participated in an inclacumab trial. This research is significant as it seeks to provide insights into the prolonged safety of inclacumab, potentially offering a new therapeutic option for SCD patients.
The intervention being tested is inclacumab, a drug administered intravenously at a dose of 30 mg/kg every 12 weeks. Inclacumab is intended to manage symptoms and improve the quality of life for patients with SCD.
The study is designed as an open-label, single-group assignment with no masking. Its primary purpose is treatment-focused, allowing all participants to receive the experimental drug, inclacumab.
The study began on March 29, 2022, and is currently active but not recruiting. The last update was submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and ensuring transparency in its development.
This update could influence Pfizer’s stock performance positively, as successful results may lead to a new treatment option for SCD, enhancing Pfizer’s market position. Investors may view this as a promising development, especially in the competitive pharmaceutical industry where innovation is key.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.